Atrogi AB, a clinical stage biotech company pioneering novel GPCR pathway-signalling modulators to transform metabolic and muscle health, today announces that the first subjects have been dosed in a ...

A new class of beta blockers designed to activate only when struck by specific wavelengths of light could allow doctors to ...

Rendering a drug effective or ineffective in a flash at the appropriate location—this is the focus of research in photopharmacology. The goal is to develop drugs that can be switched on and off with ...

Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...

Atrogi has dosed the first participants in a human study of its lead candidate ATR‑258, marking a significant step forward for the Stockholm-based biotech as it advances its next‑generation approach ...

First-in-class oral therapy ATR-258 mimics the effects of exercise - driving fat loss, increasing muscle, and improving metabolism - with broad potential as a novel treatment for muscle-sparing ...